Application Type
Patent
Application SubType
PCT National Phase
(10) Registration Number and Date
BNN20190138 08.11.2022
Status
Registered
(180) Expiration Date
(20) Filing Number and Date
BN N/2019/0138 09.07.2018
(40) Publication Number and Date
BN N/2019/0138
A
08.11.2022
(86) PCT Filing Number and Date
(87) PCT Publication Number and Date
(85) National Entry Date
(30) Priority Details
US 62/530,436
10.07.2017
(51) IPC Classes
(71/73) Applicant
(72) Inventor
(EN) LI, Yiwen : c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288
(EN) SHEN, Yang : c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288
(EN) D'ANGELO, Igor Edmondo Paolo : c/o Zymeworks, Inc. 540-1385 West 8th Avenue Vancouver V6H 3V9, British Columbia
(EN) KALOS, Michael, Dewain : c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288
(EN) LUDWIG, Dale, Lincoln : c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288
(EN) PLOWMAN, Gregory, D. : c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288
(74) Representative Name
(EN) Spruson & Ferguson Pte Ltd : c/o Ahmad Isa & Partners Unit 404-A-410A 4th Floor,Wisma Jaya Jalan Pemancha Bandar Seri Begawan BS8811 Brunei Darussalam
(54) Title
(EN) CHECKPOINT INHIBITOR BISPECIFIC ANTIBODIES
(57) Abstract
(EN)
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
--
(58) Citations